-35%

est. 2Y upside i

HealthcareSeries C

Rank

#1407

Sector

Healthcare IT

Est. Liquidity

~3Y

Data Quality

Data: Medium

Akasa presents a moderate upside opportunity for a job seeker, driven by its strong competitive moat in generative AI for healthcare RCM and a large, growing market.

Last updated: March 10, 2026

Bull (36%)+200%

Akasa's proprietary generative AI and custom large language models, trained on health system data, enable it to significantly outcompete legacy RCM providers and differentiate from incumbent EHRs. This leads to rapid customer acquisition and expansion, pushing annual recurring revenue (ARR) to over $200M within two years and justifying a $2.25B+ valuation at a premium multiple, representing a 3x return on current valuation.

Base (29%)+50%

Akasa continues its strong growth trajectory, expanding its customer base and enhancing its AI-powered RCM platform. It maintains its competitive edge against traditional RCM vendors but faces increasing, albeit manageable, competition from evolving AI solutions offered by major EHR incumbents. Revenue reaches $100M-$120M ARR, leading to an acquisition or IPO at a $1.125B valuation, a 1.5x return.

Bear (35%)-50%

Dominant incumbent EHRs like Epic and Oracle Health rapidly advance their native AI RCM capabilities, potentially commoditizing some of Akasa's offerings. Slower-than-expected adoption due to high costs and operational constraints in hospitals limits Akasa's growth. This results in a down round or acquisition at a significantly reduced valuation of $375M, wiping out a substantial portion of common stock value due to liquidation preferences.

Est. time to liquidity~3.0 years

Preference Stack Risk

high

Based on an estimated $750M valuation for the Series C round, investors hold $205M in liquidation preferences ahead of common stock. In an exit at or below $750M, common stock value would be significantly impacted.

Dilution Risk

moderate

As a Series C company, Akasa may require additional funding rounds before an IPO or acquisition, which could lead to further dilution of existing equity holders.

Secondary Liquidity

limited

While secondary markets exist for private company shares, activity for Akasa is currently low, indicating limited liquidity for employees.

Deployment Customer Engagement — 2 roles

General & Administration — 1 role

Marketing — 1 role

Product — 1 role

Sales & Customer Success — 1 role

View all 15 open roles at Akasa →

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on Akasa's data — designed to show you've done your homework.

  • 1

    “Given the increasing investment by incumbents like Epic and Oracle Health into generative AI for RCM, how does Akasa plan to maintain its differentiated competitive moat and avoid commoditization in the long term?”

  • 2

    “With the reported $30M increase in gross yield for healthcare providers, how does Akasa plan to scale this value proposition to significantly grow its ARR and penetrate a larger portion of the $101.2B Serviceable Addressable Market (SAM)?”

  • 3

    “As a Series C company with significant funding, how is Akasa thinking about the path to a liquidity event for employees, and what are the company's plans regarding potential secondary liquidity or tender offers in the next 2-3 years?”

Community

Valuation Sentiment

Our model estimates -35% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.